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ABSTRACT 
Prostate cancer (PCa) is one of the major public health problems in Western countries. 
Recently, the TMPRSS2:ERG gene fusion, which results in the aberrant expression of the 
transcription factor ERG, has been shown to be the most common gene rearrangement in PCa. 
Previous studies have determined the contributions of this fusion in PCa disease initiation 
and/or progression in vitro and in vivo. In this study on TMPRSS2:ERG regulation in PCa, we 
used an androgen receptor (AR) and TMPRSS2:ERG fusion double-negative prostate cancer 
cell model: PC3c. In three cell clones with different TMPRSS2:ERG expression levels, 
ectopic expression of the fusion resulted in significant induction of cell migration and 
invasion in a dose-dependent manner. In agreement with this phenotype, high-throughput 
microarray analysis revealed that a set of genes, functionally associated with cell motility and 
invasiveness, were deregulated in a dose-dependent manner in TMPRSS2:ERG-expressing 
cells. Importantly, we identified increased MMP9 and PLXNA2 expression in 
TMPRSS2:ERG-positive PCa samples, and their expression levels were significantly 
correlated with ERG expression in a PCa cohort. In line with these findings, there was 
evidence that TMPRSS2:ERG directly and positively regulates MMP9 and PLXNA2 
expression in PC3c cells. Moreover, PLXNA2 upregulation contributed to TMPRSS2:ERG-
mediated enhancements of PC3c cell migration and invasion. Furthermore, and importantly, 
PLXNA2 expression was upregulated in metastatic PCa tumors compared to localized primary 
PCa tumors. This study provides novel insights into the role of the TMPRSS2:ERG fusion in 
PCa metastasis. 
 
Key words: Prostate cancer, TMPRSS2:ERG fusion, Migration, Invasion, MMP9, PLXNA2. 
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INTRODUCTION 
Prostate cancer (PCa) is one of the most prevalent malignancies and a leading cause of 
cancer-related deaths affecting men in Western countries (1). Recent PCa cytogenetic and 
genomic studies have highlighted several critical genomic alterations involved in disease 
onset and/or progression (2). Of these, genomic rearrangements leading to the aberrant 
expression of the E-twenty-six (ETS) family of transcription factors in PCa is considered as a 
hallmark (3, 4). The most frequent genomic rearrangement in PCa is the fusion of the ETS-
related gene (ERG) with 5' regulatory elements of the androgen receptor (AR)-responsive 
transmembrane protease serine 2 (TMPRSS2), which has been identified in 40% to 70% of 
PCa patient samples (3). The TMPRSS2:ERG gene fusion leads to aberrant expression of full 
length and/or N-terminal-truncated ERG transcription factors in PCa (referred to as 
TMPRSS2:ERG protein in this study) (5). 
The association between TMPRSS2:ERG fusion and PCa clinical outcome has not yet been 
clearly established. Some studies have shown that this gene fusion is not significantly 
associated with PCa disease progression or prognosis (6-8); however, other studies have 
demonstrated that it is associated with favorable (9, 10) or poor clinical outcomes (11-16). 
Functional studies on the role of TMPRSS2:ERG in PCa have been performed using PCa cell 
lines as well as mouse models. Although some reports have demonstrated that ectopic 
TMPRSS2:ERG expression in the prostate is sufficient to induce prostatic intraepithelial 
neoplasia (PIN) in mice, a pre-malignancy form of PCa (17, 18), others have highlighted how 
TMPRSS2:ERG expression cooperates with other genomic alterations, such as PTEN 
haploinsufficiency, constitutive PI3K/AKT activation or AR signaling, to promote PCa cell 
migration, invasion and disease progression (19-21). Using next-generation sequencing 
technologies, recent studies aiming to identify TMPRSS2:ERG direct target genes in 
established PCa cell models have provided further evidence that ERG can modulate the 
 4 
 
output of AR target genes (22-24). These studies provide functional insights into the role of 
TMPRSS2:ERG in PCa initiation and/or progression. 
Nevertheless, PCa is considered as a multifocal disease, because primary PCa tumors are 
mainly composed of multiple, genetically distinct cancer cells (2, 25-27). Regarding 
TMPRSS2:ERG status and the corresponding TMPRSS2:ERG protein expression profile, a 
significant prevalence of inter- and/or intra-focal heterogeneity has been also observed in 
several PCa cohorts (28-31). This raises the possibility that the differentially expressed 
TMPRSS2:ERG protein can control variable transcriptional programs in genetically distinct 
PCa cells. It is therefore necessary to perform studies on different PCa cell models. 
In this study, we examined the role of TMPRSS2:ERG using an established PCa cell model, 
PC3c, which was previously isolated from AR and TMPRSS2:ERG double-negative PC3 cells 
(32). In vivo studies have revealed that PC3c cells can induce mixed lesions in bone (32), a 
commonly observed complication in PCa patients with advanced disease (33). Here, we 
demonstrate that ectopic expression of TMPRSS2:ERG fusion increases PC3c cell migration 
and invasion in a dose-dependent manner. High-throughput transcriptomic studies revealed 
that a set of genes related to cell motility and invasiveness is deregulated in TMPRSS2:ERG-
expressing cells in a dose-dependent manner. We further demonstrate that TMPRSS2:ERG 
directly and positively regulates MMP9 (Metalloproteinase 9) and PLXNA2 (Plexin A2) 
expression in PC3c cells, and that PLXNA2 upregulation contributes to the TMPRSS2:ERG-
mediated PC3c cell migration and invasion. 
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RESULTS 
Ectopic TMPRSS2:ERG expression leads to phenotype changes in PC3c cells. 
Previous studies have identified diverse TMPRSS2:ERG fusion transcripts in human PCa 
samples, and the most frequent variant is composed of exon 1 of the TMPRSS2 gene 
(NM_005656) fused to exon 4 of the ERG gene (NM_004449) (5, 34). In addition, the 
presence of a 72bp exon in fusion gene transcripts may contribute to a more aggressive 
phenotype (35). We therefore used the TMPRSS2:ERG fusion isoform that includes exon 1 of 
TMPRSS2 fused to exon 4 of ERG with the presence of the 72bp exon (Figure 1a). 
Three TMPRSS2:ERG-expressing clones were included in this study, designated as H clone 
(high), M clone (moderate) and L clone (low), according to their ERG mRNA expression 
levels (Figure 1b). ERG mRNA levels in H cells were 2-fold and 10-fold higher than in M 
cells and in L cells respectively, whereas no endogenous ERG mRNA was found in pcDNA 
control cells or in parental PC3c cells. In particular, ERG expression in H cells was only about 
50% of that in VCaP cells (endogenous TMPRSS2:ERG-expressing PCa cells), and 
comparable to endogenous full-length ERG expression in HUVEC cells, suggesting that 
TMPRSS2:ERG expression levels in our cell models were not excessive. As expected, high, 
moderate and low expression levels of TMPRSS2:ERG protein were only found respectively 
in H, M and L cells, and not in control cells or in parental PC3c cells (Figure 1c). In addition, 
compared to VCaP cells, TMPRSS2:ERG expression in H cells was lower (Supplementary 
Figure S1). 
A comparison of H, M and L cell morphology to that of control cells showed that, where 
control cells were round and clustered, H cells were more elongated and scattered (Figure 2a). 
This morphological change was also observed, to a lesser extent, in M cells, but nearly absent 
in L cells (Figure 2a). Next, we examined whether the ectopic TMPRSS2:ERG expression 
could have an impact on PC3c cell proliferation. Surprisingly, no significant cell proliferation 
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changes were observed in H, M and L cells compared to control cells (Figure 2b), suggesting 
that TMPRSS2:ERG fusion contributes to PCa initiation and/or progression in a different way. 
Accordingly, ectopic TMPRSS2:ERG expression significantly increased PC3c cell migration 
in a membrane-based assay system (Figure 2c), as well as its invasiveness in a Matrigel-based 
system (Figure 2d). Interestingly, among H, M and L cells, the enhancements of cell motility 
and invasiveness seemed to depend on TMPRSS2:ERG expression levels: compared to control 
cells, H cells showed the most significant induction of cell migration (3.5 fold) and invasion 
(7.5 fold); whereas M cell migration (1.7 fold) and invasion (3.4 fold) were higher than those 
of L cells (migration: 1.2 fold; invasion: 1.2 fold) (Figure 2c and 2d). These results provide in 
vitro evidence that TMPRSS2:ERG promotes, in a dose-dependent manner, PC3c cell 
migration and invasion, two crucial attributes of cancer cell metastasis. 
Genome-wide expression analysis reveals potential TMPRSS2:ERG target genes and their 
associated cell motility and invasiveness functions. 
To decipher the molecular mechanisms that underlie TMPRSS2:ERG-mediated PC3c cell 
migration and invasion enhancements, we investigated global gene expression changes in H, 
M and L cells using Agilent 44k Whole Human Genome Expression arrays. Compared to 
control cells, 1673 genes showed significant differential expression (adjusted P-value <0.01) 
in H cells (809 upregulated genes and 864 downregulated genes) (Figure 3a), and 446 genes 
were differentially expressed in M cells (267 upregulated genes and 179 downregulated 
genes), whereas only 191 genes with differential expression were identified in L cells (101 
upregulated genes and 90 downregulated genes). Therefore, the quantity of deregulated genes 
identified in H, M and L cells also appeared to rely on TMPRSS2:ERG expression levels in 
PC3c cells. 
A comparison of H, M and L cell transcriptomic profiles revealed that 126 genes were 
commonly deregulated in H, M and L cells (hereafter referred to as “common deregulated 
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genes”), including 64 common upregulated genes and 62 common downregulated genes 
(Figure 3b, Supplementary Table S2 and S3). In particular, about 50% of these 126 common 
deregulated genes showed high, moderate and low expression levels in TMPRSS2:ERG-
expressing H, M, L cells, respectively (Figure 3b and Supplementary Table S2 and S3). The 
“dose-dependent” expression profile of these genes suggested that they could be direct target 
genes of TMPRSS2:ERG. Among these genes, we noted the striking upregulation of PLAT 
(Tissue-type plasminogen activator), a well-known TMPRSS2:ERG target gene in PCa (4, 36, 
37). Moreover, the over-expression of some of these genes has been shown to be associated 
with PCa progression and poor clinical outcomes, such as CD44 (38), MMP9 (39) and FSCN1 
(Fascin homolog 1) (40). To understand the overall functional significance of these common 
126 deregulated genes, we used the DAVID gene ontology analysis (41). Among the top 
Gene Ontology (GO) terms, we noted that “cell motion”, “cell migration” and 
“metalloendopeptidase activity”, were upregulated, whereas “transcription” and “regulation 
of apoptosis” were downregulated (Figure 3c). Taken together, these transcriptomic studies 
were in agreement with the observed enhancements of PC3c cell migration and invasion, and 
further highlighted the TMPRSS2:ERG role in the PCa cell metastasis process. 
Turning to the identification of TMPRSS2:ERG direct target genes in PCa, we focused on 
two candidate target genes in the following studies. The first one was MMP9, also known as 
Gelatinase B, which has been shown to be associated with PCa progression (39), and also 
regulated by other ETS transcription factors in diverse types of cancer cells including PCa (42, 
43). However, it was not clear whether TMPRSS2:ERG could directly regulate MMP9 
expression in PCa. The second potential target gene was PLXNA2, a type I trans-membrane 
glycoprotein that functions as a receptor for Semaphorins. Together with other Plexins, it was 
initially considered to mediate axon guidance during development (44). However, recent 
studies have revealed Semaphorin-Plexin signaling outside of the nervous system, providing 
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additional information about this signaling in cancer (45). For instance, PLXNB1 (Plexin B1) 
gene mutations in human PCa samples have been shown to be associated with PCa cell 
motility and invasion enhancements (46). These findings, together with the phenotype 
observed in H, M and L cells, prompted us to further investigate whether TMPRSS2:ERG 
could directly control MMP9 and PLXNA2 expression to increase PCa cell migration and 
invasion.  
MMP9 and PLXNA2 expression levels were associated with TMPRSS2:ERG expression in 
human PCa samples 
To investigate whether MMP9 and PLXNA2 are genuine target genes of TMPRSS2:ERG in 
PCa, we first examined their expression in human PCa samples. We used RNA from a PCa 
cohort composed of 52 human prostatectomy specimens from the Tumor Tissue Bank, C2RC, 
Lille University Hospital (CHRU Lille) (Supplementary Table S4). Among these PCa 
samples, we found, using TMPRSS2:ERG-specific primers (4), 32 samples that showed 
detectable TMPRSS2:ERG fusion transcripts (61.5%). In this PCa cohort, MMP9 and 
PLXNA2 expression levels were significantly higher in TMPRSS2:ERG-positive PCa samples 
than in TMPRSS2:ERG-negative samples (P=0.0055 and P<0.0001 respectively) (Figures 4a 
and 4b). 
To further examine the associations between TMPRSS2:ERG and its potential targets, MMP9 
and PLXNA2, we performed a two-tailed non-parametric Spearman correlation analysis. 
Given the heterogeneity of TMPRSS2:ERG transcripts detected in PCa samples (5, 34), it is 
difficult to design universal specific primers to accurately quantify total TMPRSS2:ERG 
expression. We therefore used ERG-specific primers that could detect not only ERG 
transcripts, but also TMPRSS2:ERG transcripts. Importantly, high ERG expression was 
detected only in TMPRSS2:ERG-positive PCa samples, whereas ERG expression in fusion 
negative PCa samples was very low (Supplementary Figure S2), suggesting that, in this PCa 
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cohort, high-level ERG transcripts may be a direct consequence of the presence of 
TMPRSS2:ERG fusion. Spearman correlation analysis showed that MMP9 expression was 
significantly correlated with ERG expression (R=0.4287, P=0.0015) (Figure 4c), as was 
PLXNA2 expression (R=0.6178, P<0.001) (Figure 4d). Thus, MMP9 and PLXNA2 expression 
levels were upregulated in TMPRSS2:ERG-positive PCa specimens, and their expression 
levels were correlated with ERG expression in PCa samples. 
TMPRSS2:ERG directly and positively regulates MMP9 expression in PCa cells 
To determine whether MMP9 gene expression was directly controlled by TMPRSS2:ERG in 
PCa cells, we first performed a chromatin immunoprecipitation assay (ChIP) in H cells and 
control cells. By analyzing the promoter region of the MMP9 gene, we found a putative ETS-
binding site (EBS) within 1 kb from the MMP9 transcription start site (TSS) (Figure 5a, top 
panel). ChIP assay showed significant binding of TMPRSS2:ERG on this EBS in H cells 
(Figure 5a, bottom panel), whereas no TMPRSS2:ERG binding was found on this EBS in 
control cells, or in the promoter region of GAPDH gene which does not contain any 
functional EBS, suggesting direct and specific TMPRSS2:ERG binding to the MMP9 
promoter region in PC3c cells. 
Next, dose-dependent upregulation of MMP9 gene expression was confirmed by RT-qPCR in 
H, M and L cells (Figure 5b). In addition, we found that ectopic expression of 
TMPRSS2:ERG in DU145 cells, another AR and fusion double-negative PCa cell model, also 
resulted in increased MMP9 expression (Figure 5c and Supplementary Figure S3). Because it 
has been shown that secreted MMP9 has an important role in extracellular matrix remodeling 
during cancer progression (47), we further investigated secreted MMP9 levels in 
TMPRSS2:ERG-expressing cells using a gelatin zymography assay. As expected, compared to 
control cells, more secreted MMP9 was found in TMPRSS2:ERG-expressing H and M cell 
conditioned mediums (Figure 5d). In particular, the cell gelatin degradation assay highlighted 
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the association between increased MMP9 secretion and the enhancement of gelatin matrix 
degradation in TMPRSS2:ERG-expressing H cells (Figure 5e and Supplementary Figure S4). 
Moreover, the knockdown of TMPRSS2:ERG in H cells using pooled ERG siRNA 
(Supplementary Figure S5) led to over 40% reduction of MMP9 expression (Figure 5f), as 
well as decreased MMP9 secretion (Figure 5g). Similar results were also observed in M cells 
(Supplementary Figure S6) as well as in TMPRSS2:ERG-expressing DU145 cells 
(Supplementary Figure S7). Taken together, these results indicate that TMPRSS2:ERG is 
capable to directly and positively regulate MMP9 in PCa cells. 
PLXNA2 is directly and positively regulated by TMPRSS2:ERG in PCa cells 
Plexin A2 (PLXNA2) is another candidate TMPRSS2:ERG target gene identified by our 
transcriptomic studies (Figure 3b), and its expression was found to be upregulated in 
TMPRSS2:ERG-positive PCa samples and correlated with ERG expression in PCa specimens. 
A putative EBS, located within 1 kb from the PLXNA2 gene TSS, was found in the PLXNA2 
promoter region (Figure 6a, top panel). The ChIP assay showed significant TMPRSS2:ERG 
binding on this EBS in H cells, but not in control cells (Figure 6a, bottom panel). Moreover, 
this binding was absent in the irrelevant GAPDH promoter region, indicating TMPRSS2:ERG 
directly and specifically binds to the PLXNA2 promoter in PC3c cells. 
The dose-dependent increase of PLXNA2 expression was then confirmed in TMPRSS2:ERG-
expressing H, M and L cells compared to control cells (Figure 6b). In addition, PLXNA2 
upregulation was also observed in TMPRSS2:ERG-expressing DU145 cells (Figure 6c and 
Supplementary Figure S3). An immunofluoresence assay also showed PLXNA2 protein 
induction in TMPRSS2:ERG-expressing H cells (Figure 6e, left panel). Importantly, 
TMPRSS2:ERG knockdown in H cells resulted in about 50% reduction of PLXNA2 mRNA 
levels (Figure 6d), as well as PLXNA2 protein immunostaining (Figure 6e, right panel). 
Similar results were observed in M cells (Supplementary Figure S6) and TMPRSS2:ERG-
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expressing DU145 cells (Supplementary Figure S7). These results therefore highlight that 
TMPRSS2:ERG can directly and positively regulate PLXNA2 expression in PCa cells. 
PLXNA2, but not MMP9, contributes to TMPRSS2:ERG-induced PC3c cell migration and 
invasion in vitro. 
To further explore whether MMP9 and PLXNA2 were direct mediators of TMPRSS2:ERG-
induced pro-motility and pro-invasion phenotypes observed in PCa cells, we performed 
migration and invasion assays using H cells in which ERG, MMP9 and PLXNA2 were 
knocked down, respectively. The pooled MMP9 siRNA efficiently knocked down MMP9 
expression (Supplementary Figure S8a) as well as MMP9 secretion in H cells (Supplementary 
Figure S8b). Efficient PLXNA2 knockdown effects were as well observed using pooled 
PLXNA2 siRNA in H cells (Figure 7a and 7b). 
In H cells, ERG knockdown dramatically decreased cell migration by over 50% (Figure 7c), 
and cell invasion by 70% (Figure 7d), indicating that the inductions of cell migration and 
invasion are specific to ectopic TMPRSS2:ERG expression. Surprisingly, MMP9 knockdown 
had no significant effect on cell migration or invasion in H cells (Supplementary Figure S8c 
and S8d), whereas PLXNA2 knockdown in H cells resulted in a 30% decrease in cell 
migration (Figure 7c) and a 20% decrease in cell invasion (Figure 7d). Hence, these findings 
demonstrate that PLXNA2 upregulation, but not MMP9 upregulation, may contribute, at least 
in part, to TMPRSS2:ERG-mediated induction of PC3c cell migration and invasion in vitro. 
Furthermore, increased cell motility and invasiveness are considered as attributes commonly 
acquired by PCa cells during metastatic progression (48). Whether PLXNA2 expression is 
associated with metastatic PCa remains unclear. We therefore analyzed PLXNA2 expression 
in microarray datasets from three independent PCa cohorts (49-51). As shown in Figures 7e, 
7f and 7g, compared to primary PCa samples, PLXNA2 expression levels were significantly 
higher in the metastatic PCa, substantiating its potential role in PCa metastasis. 
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DISCUSSION 
Although the presence of chromosomal abnormalities have commonly been observed in 
hematologic malignancies and sarcomas (52), it was only in 2005, using conceptually new 
bioinformatics approaches, that the first gene fusions were identified in a large proportion of 
PCa (4). While the gene fusions initially found in PCa were ETS transcription factors (ERG 
and ETV1) fused to the 5' part of the prostate-specific gene TMPRSS2, it is now clear that they 
may involve other ETS family members (i.e., Fli-1, ELK4), novel 5’ partners and a class of 
non-ETS-based fusions (3). However, the TMPRSS2:ERG fusion remains the most prevalent 
chromosomal rearrangement in PCa (3). To date, this fusion has been identified not only in 
androgen-responsive PCa, but also in androgen-refractory PCa (16). 
Here, using three AR-negative PC3c cell clones with different TMPRSS2:ERG expression 
levels, we demonstrated that ectopic expression of TMPRSS2:ERG can induce, in a dose-
dependent manner, PC3c cell motility and invasiveness. These findings are in agreement with 
the role of the TMPRSS2:ERG fusion as revealed using various PCa cell models (4, 18, 21, 35, 
53). Importantly, inhibition of endogenous TMPRSS2:ERG expression in AR-positive VCaP 
cells significantly reduced cell invasiveness (17, 18). Given the diverse genetic backgrounds 
of PCa cell models used in studies, the common function of TMPRSS2:ERG fusion is to 
improve PCa cell motility and invasiveness. Furthermore, since TMPRSS2:ERG-induced cell 
migration and invasion have been shown in AR-positive and -negative PCa cells, this function 
does not seem to be associated with the AR status of PCa cells. Increased cell motility and 
invasiveness are the essential hallmarks of cancer, as well as prerequisites for local tumor 
progression and metastasis (48). Interestingly, recent clinical studies also revealed the 
presence of TMPRSS2:ERG fusion in circulating tumor cells isolated from PCa patients with 
metastatic disease and in castration-resistant PCa patients (54, 55). In addition, 
TMPRSS2:ERG-positive foci in multifocal PCa have a greater predilection for lymph node 
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metastasis (56, 57). These clinical findings highlight the potential role of TMPRSS2:ERG in 
PCa metastasis. 
Increased cell motility and invasiveness are also associated with cells adopting a 
mesenchymal phenotype (58). The epithelial-to-mesenchymal transition (EMT) is considered 
to be one of key steps for cells to acquire metastatic adaptation (59). Three previous studies 
have also demonstrated that EMT is one of the consequences of TMPRSS2:ERG expression in 
PCa cell models (37, 53, 60). Accordingly, PC3c cells with high TMPRSS2:ERG expression 
(H cells) demonstrated a more elongated and scattered mesenchymal morphology. However, 
the absence of differential expression of EMT markers, such as E-Cadherin, Vimentin, Twist1 
and Snail in our cell models (Supplementary Figure S9), raised two questions that need to be 
addressed in future studies: 1) Among our cell models (H, M and L cells), the highest 
TMPRSS2:ERG expression was only 50% of that found in VCaP cells; is there a threshold of 
ERG expression necessary to induce EMT in PCa cells? 2) Is TMPRSS2:ERG-induced EMT 
independent of AR signaling? 
MMP9 expression has been shown to be correlated with increased invasive and metastatic 
phenotypes in various tumor types including prostate cancer (39, 61, 62). Here, we showed 
that MMP9 was positively and directly regulated by TMPRSS2:ERG in PC3c cells and its 
expression was correlated with ERG expression in PCa samples. In fact, several transcription 
factors, such as NF-κB, SP-1, AP-1 and ETS have been shown to control MMP9 expression 
in physiological and pathological conditions (63-65). Although it has been reported that ETS-
1 promotes the invasiveness of paclitaxel-resistant and hormone-refractory PCa cells by 
increasing MMP9 expression (66), a recent study reported that SPDEF, another ETS 
transcription factor, suppresses prostate cancer cell invasion through the repression of MMP9 
expression (42). Together with our results, these findings highlight the importance of the 
functional specificity of ETS transcription factors in controlling MMP9 expression in PCa. 
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Furthermore, although increased secretion of MMP9 and corresponding gelatin matrix 
degradation were observed in our cell model, MMP9 knockdown did not impair 
TMPRSS2:ERG-induced cell migration or invasion in the membrane-based transwell assays. 
Similar results have also been observed in TMPRSS2:ERG or ERG-expressing RWPE-1 and 
BPH-1 cells treated with the pan-MMP inhibitor or a MMP2/9 specific inhibitor (4, 18), 
suggesting that, under membrane-based transwell assay systems, increased MMP9 expression 
is not essential for TMPRSS2:ERG-induced cell migration and invasion. Of particular interest, 
MMP9 has been shown to trigger the release of the matrix-bound VEGF, thus promoting 
tumor angiogenesis (67), and remodeling the pro-metastatic microenvironment of the 
metastatic niche (47, 68). Therefore, future studies are required to determine the role of 
MMP9 in TMPRSS2:ERG-positive PCa cells using in vivo models. 
Plexin receptors and their Semaphorin ligands were initially identified as evolutionarily 
conserved axon-guidance cues in the nervous system (69). However, increasing evidence 
highlights their role outside the nervous system, and particularly in cancer metastasis and 
progression (45). In particular, there is supporting evidence that somatic aberrations of 
Plexins and Semaphorins are involved in pancreatic carcinogenesis (70). Although their 
functions are poorly understood in PCa, Plexin receptors and its Semaphorin ligands have 
been shown to be expressed in diverse PCa cell lines and tissues (71). The overexpression of 
PLXNB1 with somatic missense mutations is functionally associated with increased PCa cell 
motility and invasiveness, as well as disease metastatic progression (46, 72). We showed in 
the present study that that TMPRSS2:ERG positively and directly regulates PLXNA2 
expression in PC3c cells. Interestingly, during mouse (73, 74) and chicken development (75, 
76), the Erg expression profile overlaps with that of Plxna2 in migrating neural crest cells and 
aorta, suggesting the possible direct regulation of Plxna2 by the Erg transcription factor in 
development process. Moreover, other transcription factors may also control PLXNA2 
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expression. For example, GATA6 has been shown to directly regulate PLXNA2 expression 
during human cardiac outflow tract development (77). Furthermore, the pleiotropic signals 
mediated by Semaphorin-Plexin have been shown to positively or negatively control multiple 
functions in tumor cells, including their migration and invasion abilities (45). We showed that 
the upregulation of PLXNA2 contributes, at least in part, to TMPRSS2:ERG-induced PC3c 
cell migration and invasion. In agreement with these findings in vitro, analysis of microarray 
datasets provided evidence that PLXNA2 expression is up-regulated in metastatic PCa, 
supporting the potential involvement of PLXNA2 in PCa metastatic spread. 
In summary, using an AR-negative PCa model, we confirmed the important role of 
TMPRSS2:ERG in PCa cell migration and invasion, and identified two “cell motility”- and 
“invasiveness”-related direct target genes, MMP9 and PLXNA2, providing novel insights into 
the role of TMPRSS2:ERG in PCa metastasis. 
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MATERIALS AND METHODS 
Cell culture and Chemical reagents 
PC3c cells (32) and DU145 cells (ATCC) were cultured in DMEM supplemented with 10% 
fetal bovine serum and sub-cultured every 3-4 days. Unless otherwise stated, all chemical 
reagents were from Sigma-Aldrich. 
Generation of plasmids and retrovirus constructs 
The TMPRSS2:ERG cDNA was isolated from a fusion-positive PCa patient sample, and sub-
cloned into a pcDNA3.1(+) (Invitrogen) or retrovirus pLPCX vector (Clontech). The primers 
used for cloning are listed in Supplementary Table S1. Amplified plasmids were purified on 
NucleoBond Xtra Midi endotoxin-free columns (Macherey-Nagel) and sequenced prior to use. 
Generation of TMPRSS2:ERG-expressing cells  
Low passage PC3c cells were transfected with a TMPRSS2:ERG expression vector or empty 
pcDNA vector using FuGENE® 6 Reagent (Roche) according to the manufacturer’s 
instruction, then selected in routine culture medium containing 400 mg/mL G418 antibiotic 
(Life Technologies) for 3 weeks. The pLPCX- or pLPCX/TMPRSS2:ERG-containing 
retroviruses were transduced into DU145 cells to generate TMPRSS2:ERG-expressing cells 
according to the manufacturer’s instructions (Clontech).  
Short interfering RNAs (siRNA) transfection 
Pre-designed pooled siRNA were obtained from Dharmaco-Termo Scientific. Cells were 
transfected with the siRNA (50 nM) using Lipofectamine 2000 reagent (Invitrogen) according 
to the manufacturer’s instructions. Gene knockdown effects were evaluated after 72 h of 
transfection. The siRNA used in this study were siERG (ON-TARGETplus SMARTpool L-
003886-00), siMMP9 (ON-TARGETplus SMARTpool L-005970-00), siPLXNA2 (ON-
TARGETplus SMARTpool L-021532-01) and the control siRNA (ON-TARGETplus Non-
targeting Pool D-001810-10). 
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Protein extraction and immunoblotting 
Proteins were extracted and immunoblotted (Western Blotting) as described previously (78). 
Antibodies used in immunoblotting were: rabbit monoclonal anti-ERG (Epitomics 2085, 
dilution 1:1 000), mouse monoclonal anti β-ACTIN (Sigma Clone AC-15, dilution 1:10 000), 
rabbit polyclonal anti HPRT (Santa Cruz sc-20975, dilution 1:1 000), Rabbit IgG-HRP (GE 
Healthcare NA934V, dilution 1:10 000) and Mouse IgG-HRP (Santa Cruz, 1:10 000). 
Cell proliferation, migration and invasion assay 
Cell proliferation assays were performed in quadruplicate using CellTiter-Glo® kit (Promega) 
in 96-well plate (2 500 cells/well) according to the manufacturer’s recommendations, and 
luminescence was measured using a Centro LB 960 microplate luminometer (Berthold) at 
indicated times. 
Cell migration assays and cell invasion assays were performed with 100 000 cells in triplicate 
using a FluoroBlok™ 8 µm pores 24-well insert system (BD Biosciences) and 24-well 
BioCoat™ Tumor Invasion System (BD Biosciences) according to the manufacturer’s 
instructions. After 16 h of incubation, cells were labeled with 10 µg/mL DilC12(3) fluorescent 
dye (BD Biosciences), and the migrated or invaded cells were measured using a FLUOstar 
OPTIMA lecturer (BMG Labtech).  
Gelatin degradation assay and gelatin zymography analysis 
Gelatin degradation assay was performed as described previously (79). To perform the gelatin 
zymography assay, cells were rinsed and incubated with medium without FBS for 24 h. Then 
the conditioned mediums (CM) were collected, and total protein concentrations were 
measured and used to adjust loading quantity of CM. Equal amount of CMs were mixed with 
non-denaturing Laemmli blue loading dye, then loaded on a 7% SDS-PAGE gel containing 
0.1% (w/v) gelatin. After migration, the gel was incubated with zymogram renaturing buffer 
and zymogram developing buffer. Finally, the gel was stained with 0.5% (w/v) Coomassie 
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Blue R-250 and destained with a solution containing 40% (v/v) ethanol and 10% (v/v) acetic 
acid. 
Cell total RNA preparation and RT-qPCR 
Cell total RNA was purified using the NucleoSpin® RNA II kit (Macherey Nagel) according 
to the manufacturer’s instructions. Then, 1 µg total RNA was used to generate cDNA strand 
using the High Capacity RNA-to-cDNA kit (Applied Biosystems). Quantitative polymerase 
chain reactions (qPCRs) were performed using the Power SYBR Green PCR Master kit 
(Applied Biosystems) on a Stratagene Mx3005P qPCR System according to manufacturer’s 
instructions. Individual gene relative expression level was calculated using the 2-ΔΔCT method 
and normalized to that of the housekeeping gene 18S. Optimal primer specificity and 
efficiency were validated according to the Mx3005P qPCR System user’s guide. The primers 
used in this study can be found in Supplementary Table S1. 
Immunofluorescence 
Immunofluorescence (IF) assays were performed as described (78). The antibodies used in 
this study were monoclonal rabbit anti-ERG (Epitomics 2805, dilution 1:200), monoclonal rat 
anti-PLXNA2 (R&D Systems, MAB5486, 10 µg/mL), Alexa Fluo®-488 conjugated anti-
rabbit IgG (Invitrogen, dilution 1:500) and Alexa Fluo®-555 anti-rat IgG (Invitrogen, dilution 
1:500). Images were acquired using an LSM 710 confocal microscopy system and ZEN 2010 
software (Carl Zeiss). 
Microarray analysis 
Microarray analyses were conducted following the Two-Color Microarray-Based Expression 
Analysis Protocol (Agilent Technologies). For each sample, 1 µg of total RNA was divided 
into two equal aliquots to enable technical replication known as “dye-swap hybridization”. 
The reverse transcription and the labeling procedure were performed using the protocol 
recommended by Agilent Technologies (Low RNA Input Fluorescent Linear Amplification 
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Kit). Hybridizations were performed on Agilent Whole Human Genome 44K microarrays for 
17 hours at 65°C using the Agilent Gene Expression Hybridization kit. Arrays were washed 
and scanned using Innoscan 700 (Innopsys) and the raw data were processed and normalized 
using the Limma package (Linear Models for Microarray Data) running under the R 
environment. Gene Ontology analysis was performed using the DAVID program as described 
(41). 
Chromatin immunoprecipitation (ChIP) 
ChIP assay was performed as described (80). Antibodies used were polyclonal rabbit anti 
ERG antibody (Santa Cruz sc-353) or control rabbit IgG antibody (Santa Cruz). The genomic 
DNA was purified using NucleoSpin® Clean-up columns (Macherey-Nagel) according to 
protocol recommended by the manufacturer. Immunopreciptated genomic DNA was analyzed 
by PCR and details of the primers used can be found in Supplementary Table S1. 
Human PCa samples 
Human PCa samples (n=52) were obtained from the local tumor tissue bank, C2RC (Lille, 
France) after approval by the internal review board (CSTMT-042, 27/07/2009). Sampled and 
subsequently frozen tumor tissues originated from radical prostatectomies or trans-urethral 
prostatic resections performed at Lille University Hospitals (CHRU de Lille). All patients 
were informed and consent was obtained by the referring physician. To extract RNA, tissue 
samples were first homogenized in TRIzol® (Invitrogen), and total RNA was prepared using 
NucleoSpin® RNA II columns (Macherey-Nagel). The RNA quality and quantity were 
accessed by the Agilent 2100 Bioanalyser system. Pathological findings of these PCa samples 
can be found in Supplementary Table S4. 
Image treatment and Statistical analysis 
All images treatments were carried out using Image J or Photoshop CS software. Statistical 
analysis was performed using GraphPad Prism software. Statistical methods used in this study 
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are indicated in the corresponding figure legends. Unless otherwise indicated, all values in the 
figures are expressed as means ± SEM. 
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FIGURE LEGENDS 
Figure 1  Stable ectopic expression of the TMPRSS2:ERG gene fusion in PC3c cells. (a) 
Schematic illustration of the TMPRSS2:ERG gene fusion expression plasmid construction. (b) 
Relative ERG expression was evaluated using qPCR in three TMPRSS2:ERG-expressing 
PC3c clone cells (H: PC3c cells with high ERG expression, M: PC3c cells with medium ERG 
expression and L: PC3c cells with low ERG expression), in control pcDNA clone cells, in 
HUVEC cells, as well as in VCaP cells. The expression levels of ERG in VCaP cells were 
normalized to 1. Results were obtained from three independent triplicate experiments. (c) 
Detection of TMPRSS2:ERG protein products (N-terminal-truncated ERG protein < 55 kDa) 
in H, M, L cells, control cells and parental PC3c cells. Total cell lysates were analyzed using 
Western blotting with ERG antibody, and human HPRT immunoblotting was used as a 
loading control. 
Figure 2  Phenotype characterization of PC3c cells with ectopic TMPRSS2:ERG 
expression. (a) Phase contrast micrographs of H, M, L cells and control cells. Scale bar, 50 
µm. (b) Cell proliferation assays were performed using the CellTiter-Glo kit (Promega) in 
quadruplicate for 5 days. Three independent experiments were performed and results are 
presented as relative luminescence unit (RLU) fold change compared to the RLU measured 
on Day 0. (c) Cell migration assays were performed using the FluoroBlok™ 8 µm pore 24-
well insert system (BD Biosciences) in triplicate according to the manufacture’s 
recommendations. Results are presented as relative fluorescence unit (RFU) fold change 
compared to control cells after 16 h. ***P<0.001, *P<0.05, one-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparison test. (d) Cell invasion assays were performed 
in triplicate using the 8 µm pore 24-well BioCoat™ Tumor Invasion system (BD Biosciences) 
according to the manufacturer’s instructions. Results are presented as RFU fold change 
 32 
 
compared to control cells measured after 16 hours. ***P<0.001, one-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparison test. 
Figure 3  Transcriptomic studies of PC3c H, M and L cells. (a) Red Venn diagram shows 
809 genes, 267 genes and 101 genes are upregulated in TMPRSS2:ERG-expressing H, M and 
L cells, respectively (left panel). Comparison of upregulated genes in three clones shows an 
overlap of 64 genes commonly upregulated in TMPRSS2:ERG-expressing PC3c cells 
compared to control cells. Green Venn diagram illustrates 864 genes, 179 genes and 90 genes 
downregulated in H, M and L cells, respectively (right panel). The 62 genes located in the 
overlap are common downregulated genes in TMPRSS2:ERG-expressing PC3c cells 
compared to control cells. (b) Common genes associated with TMPRSS2:ERG ectopic 
expression in H, M, and L cells. Left panel: 64 upregulated genes; right panel: 62 
downregulated genes. The gene expression level is presented in color and average linkage 
hierarchical clustering was used to ordinate profiles. (c) Top-ranked Gene Ontology (GO) 
terms analyzed using the DAVID algorithm. GO term significances are presented as 
histograms. Red: GO terms of the 64 common upregulated genes in H, M and L cells; Green: 
GO terms of the 62 common downregulated genes in H, M and L cells. 
Figure 4  Upregulation of MMP9 and PLXNA2 in TMPRSS2:ERG-positive human PCa 
samples. (a) MMP9 mRNA expression in TMPRSS2:ERG-positive (n=32) and -negative 
(n=20) PCa samples was evaluated using RT-qPCR in triplicate. Two independent 
experiments were performed. P=0.0055, two-tailed Mann-Whitney test. (b) PLXNA2 mRNA 
expression in TMPRSS2:ERG-positive (n=32) or -negative (n=20) PCa samples using RT-
qPCR. Two independent triplicate experiments were performed. P<0.0001, two-tailed Mann-
Whitney test. (c) Scatter-plot showing relative MMP9 mRNA expression and its 
corresponding ERG mRNA expression in primary PCa samples. n=52, R=0.4287, P=0.0015, 
two-tailed non-parametric Spearman correlation test with alpha=0.05. (d) Scatter-plot 
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showing the relative PLXNA2 mRNA expression and its corresponding ERG mRNA 
expression in primary PCa samples. n=52, R=0.6178, P<0.0001, two-tailed non-parametric 
Spearman correlation test with alpha=0.05.  
Figure 5  TMPRSS2:ERG directly and positively regulates MMP9 expression in PCa 
cells. (a) A putative ETS binding site (EBS) (black oval) was identified in the MMP9 gene 
promoter region (top panel), and ChIP assays were performed to examine ERG binding in H 
cells and in control cells. The irrelevant GAPDH gene promoter (without EBS) was used for 
negative controls (bottom panel). The positions of primers used in ChIP assay are represented 
by black arrows in the top panel. (b) MMP9 expression was analyzed in the PC3c clone cells 
using RT-qPCR. (c) MMP9 gene expression was analyzed using RT-qPCR in DU145 cells 
with ectopic TMPRSS2:ERG expression. (d) Gelatin zymography was performed to analyze 
secreted MMP9 levels in PC3c clone cell conditioned mediums. Loading quantity was 
adjusted to total conditioned medium concentration. Three independent experiments were 
performed and a representative experiment is shown. (e) Gelatin degradation assays were 
performed on coverslips pre-coated with FITC-gelatin for 6 h. Ten images were taken of each 
coverslip and degradation surfaces were analyzed by Image J, then divided by cell number 
after counting DAPI- and F-Actin-positive cells to calculate relative degradation surface per 
cell. Results are presented as fold change of the degradation surface per cell relative to control 
pcDNA cells set to equal 1. Mean and SEM were calculated from two independent 
experiments with two coverslips each. ***P<0.001, two-tailed Mann-Whitney test. (f) MMP9 
gene expression was analyzed in H cells treated with control or ERG siRNA. The expression 
level in cells treated with control siRNA was normalized to 1. (g) Gelatin zymography 
showing a reduction of secreted MMP9 levels in the conditioned medium of H cells treated 
with ERG siRNA. Two independent experiments were performed and a representative 
experiment is shown. 
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Figure 6  PLXNA2 is directly and positively regulated by TMPRSS2:ERG in PCa cells. 
(a) A putative EBS was identified in the PLXNA2 gene promoter (black oval) (top panel). 
ChIP assay was performed to examine ERG binding on this EBS in TMPRSS2:ERG-
expressing H cells or in TMPRSS2:ERG-negative control cells. The irrelevant GAPDH gene 
promoter (without EBS) was used for negative controls (bottom panel). The positions of 
primers used in ChIP assay are represented by black arrows in the top panel. (b) Real-time 
PCR detection of PLXNA2 expression in PC3c clone cells. (c) PLXNA2 expression was 
analyzed in DU145 with ectopic TMPRSS2:ERG expression. (d) Analysis of PLXNA2 
expression in H cells treated with either pooled control or pooled ERG siRNA. The 
expression level in H cells treated with control siRNA was normalized to 1. (e) 
Immunofluorescent analysis (IF) of ERG and PLXNA2 expression in H cells or control cells 
(left panel), and in H cells treated with either pooled control siRNA or pooled ERG siRNA 
(right panel). Scale bar, 20 µm. 
Figure 7  PLXNA2 contributes to TMPRSS2:ERG-induced PC3c migration and 
invasion. (a) H cells were treated with pooled control or PLXNA2-specific siRNA, and 
PLXNA2 gene expression was analyzed by RT-qPCR. The expression level in H cells treated 
with control siRNA was normalized to 1. (b) IF analysis showing ERG and PLXNA2 
expression in H cells transfected with control or PLXNA2 siRNA. Scale bar, 20 µm. (c) Cell 
migration assays were performed using the FluoroBlok™ 8 µm pore 24-well insert system 
(BD Biosciences) in triplicate. TMPRSS2:ERG-expressing H cells were treated with control, 
ERG or PLXNA2 siRNA for 48 h, then migration was analyzed by measuring fluorescence 16 
h later. Results are presented as RFU fold change compared to cells treated with control 
siRNA. ***P<0.001, One-way analysis of variance (ANOVA) with Dunnett’s multiple 
comparison test. (d) Cell invasion assays were performed in triplicate on H cells, pre-treated 
with control, ERG or PLXNA2 siRNA for 48 h, using the 8 µm pore 24 well BioCoat™ 
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Tumor Invasion System (BD Bioscience). Results are also presented as RFU fold change 
compared to cells treated with control siRNA measured at 16 h later. ***P<0.001, **P<0.01, 
one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. (e) 
Comparison of PLXNA2 expression profile in primary PCa (n=13) and in metastatic PCa 
(n=20) using the dataset from Dhanasekaran et al. P=0.0002, two-tailed Mann-Whitney test. 
(f) Comparison of PLXNA2 expression profile in primary PCa (n=7) and in metastatic PCa 
(n=6) using the GDS1439 dataset. P=0.0082, two-tailed Mann-Whitney test. (g) Comparison 
of PLXNA2 expression profile in primary PCa (n=59) and metastatic PCa (n=35) using the 
GSE35988 dataset. P<0.0001, two-tailed Mann-Whitney test. 
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Gleason Score Pre-surgery PSA (ng/mL) TMPRSS2:ERG fusionPCa Samples TNM classification
Supplementary Table S4: Histo-pathological Characterization of PCa Samples (n=52)
Log 2 FC P value Log 2 FC P value Log 2 FC P value
BF210146 A_32_P158376 LOC389652 BF210146 ‐1,41791868 7,54E‐05 ‐1,35322104 1,24E‐03 ‐1,38671454 8,74E‐03
CR606969 A_32_P150040 CR606969 CR606969 ‐1,2314649 2,66E‐04 ‐1,44763614 4,24E‐04 ‐1,17659944 6,79E‐03
NM_032523 A_32_P220762 OSBPL6 Oxysterol Binding protein-like 6 ‐1,12058145 2,04E‐03 ‐1,28085046 2,33E‐03 ‐1,23966881 9,11E‐03
ENST0000036 A_24_P101651 ENST0000036 ENST00000361201 ‐1,10286513 2,13E‐03 ‐1,75148013 1,48E‐04 ‐1,41629755 2,88E‐03
NM_002781 A_32_P219970 PSG6 pregnancy specific beta-1-glycoprotein 5 ‐2,47159202 8,91E‐05 ‐1,14207606 1,63E‐03 ‐1,09511648 7,84E‐03
ENST0000051 A_32_P49284 ENST0000051 ENST00000518311 ‐1,58372159 1,52E‐04 ‐1,58382846 2,74E‐04 ‐1,27794328 4,25E‐03
NM_000101 A_23_P163506 CYBA cytochrome b-245, alpha polypeptide ‐2,44913037 7,14E‐06 ‐2,4178692 1,31E‐05 ‐2,36437005 3,98E‐04
NM_000110 A_23_P135548 DPYD dihydropyrimidine dehydrogenase ‐3,03162486 3,29E‐06 ‐1,69897541 3,16E‐04 ‐1,05290523 9,43E‐03
NM_000237 A_23_P146233 LPL lipoprotein lipase ‐1,06797162 2,24E‐04 ‐1,12289186 1,81E‐03 ‐1,28554578 3,96E‐03
NM_00101000A_24_P579356 ARHGAP28 Rho GTPase activating protein 28 ‐2,43072177 1,33E‐05 ‐1,89550863 1,77E‐04 ‐1,36599581 4,48E‐03
NM_0010424 A_24_P270728 NUPR1 nuclear protein, transcriptional regulator, 1 ‐2,29528964 1,07E‐04 ‐2,25895311 4,80E‐05 ‐2,29344887 2,35E‐03
NM_00108084A_24_P79529 CSAG2 CSAG family, member 2; CSAG family, member 3; similar to CSAG family, member 2 ‐1,01216228 3,60E‐03 ‐1,5151696 4,19E‐04 ‐1,54606854 4,05E‐03
NM_0011950 A_23_P257497 C6orf99 Homo sapiens chromosome 6 open reading frame 99 ‐1,85372067 3,74E‐05 ‐1,11099989 2,04E‐03 ‐1,09733037 8,08E‐03
NM_001206 A_23_P415401 KLF9 Kruppel-like factor 9 ‐1,4574446 2,88E‐05 ‐1,3958477 5,18E‐04 ‐1,48405439 2,58E‐03
NM_001432 A_23_P41344 EREG epiregulin ‐2,55901413 1,70E‐05 ‐1,90571418 1,10E‐04 ‐1,41329737 4,51E‐03
NM_001657 A_23_P259071 AREG amphiregulin; amphiregulin B ‐1,62107875 2,37E‐05 ‐1,33552944 1,18E‐03 ‐1,12549374 8,48E‐03
NM_001740 A_23_P21092 CALB2 calbindin 2 ‐2,92119518 4,78E‐06 ‐1,85880197 1,16E‐04 ‐1,72202989 1,66E‐03
NM_001902 A_23_P126103 CTH cystathionase (cystathionine gamma-lyase) ‐1,32233196 3,58E‐05 ‐1,4561616 4,15E‐04 ‐1,11619076 7,13E‐03
NM_002467 A_23_P215956 MYC v-myc myelocytomatosis viral oncogene homolog (avian) ‐0,63748745 1,47E‐02 ‐0,88129184 7,71E‐03 ‐1,02104782 1,18E‐02
NM_002782 A_23_P108170 PSG6 pregnancy specific beta-1-glycoprotein 6 ‐2,49631972 5,45E‐06 ‐1,44671338 4,25E‐04 ‐1,22506964 6,07E‐03
NM_002784 A_23_P39309 PSG9 pregnancy specific beta-1-glycoprotein 9 ‐2,57434014 7,45E‐06 ‐1,41470487 1,05E‐03 ‐1,25086787 5,20E‐03
NM_003196 A_24_P327886 TCEA3 transcription elongation factor A (SII), 3 ‐1,54030146 1,13E‐04 ‐1,26681864 9,45E‐04 ‐1,38941773 4,47E‐03
NM_003280 A_23_P166823 TNNC1 troponin C type 1 (slow) ‐3,17514396 1,17E‐06 ‐1,72710138 3,69E‐04 ‐1,22870263 5,73E‐03
NM_003597 A_23_P44505 KLF11 Kruppel-like factor 11 ‐1,22256751 7,22E‐04 ‐1,20407056 1,22E‐03 ‐1,13637723 7,18E‐03
NM_003714 A_23_P110686 STC2 stanniocalcin 2 ‐1,10457472 2,16E‐04 ‐1,43759507 4,65E‐04 ‐1,14723848 7,13E‐03
NM_004080 A_23_P61919 DGKB diacylglycerol kinase, beta 90kDa ‐4,03766126 1,87E‐06 ‐1,23710948 1,02E‐03 ‐1,07648412 9,22E‐03
NM_004083 A_23_P21134 DDIT3 DNA-damage-inducible transcript 3 ‐1,3660376 7,93E‐04 ‐1,85167646 2,16E‐04 ‐1,48448283 2,99E‐03
NM_004420 A_23_P390528 DUSP8 dual specificity phosphatase 8 ‐1,25972708 3,35E‐03 ‐1,01322655 3,26E‐03 ‐1,38583012 4,30E‐03
NM_004563 A_23_P140207 PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) ‐1,18098063 6,73E‐04 ‐1,37479311 5,52E‐04 ‐1,35664248 3,35E‐03
NM_004577 A_23_P251984 PSPH phosphoserine phosphatase-like; phosphoserine phosphatase ‐1,2359542 2,30E‐04 ‐1,35077206 6,05E‐04 ‐1,1716885 5,79E‐03
NM_004864 A_23_P16523 GDF15 growth differentiation factor 15 ‐2,42366784 8,20E‐05 ‐1,69858499 4,38E‐04 ‐2,39238588 4,29E‐04
NM_005194 A_23_P411296 CEBPB CCAAT/enhancer binding protein (C/EBP), beta ‐0,87343114 2,89E‐03 ‐1,10199141 2,75E‐03 ‐1,12832902 7,56E‐03
NM_005213 A_23_P170233 CSTA cystatin A (stefin A) ‐2,28500829 3,30E‐05 ‐2,66372862 8,38E‐06 ‐1,78687604 1,39E‐03
NM_005367 A_23_P252928 MAGEA12 melanoma antigen family A, 12 ‐1,35694933 1,31E‐03 ‐1,64465938 3,13E‐04 ‐2,00564759 5,07E‐04
NM_005557 A_23_P38537 KRT16 keratin 16; keratin type 16-like ‐2,35504973 1,18E‐05 ‐1,65904918 3,56E‐04 ‐1,63495607 2,17E‐03
NM_006905 A_23_P50697 PSG1 pregnancy specific beta-1-glycoprotein 1 ‐2,84056045 3,20E‐06 ‐1,69333899 1,85E‐04 ‐1,2473813 4,48E‐03
NM_007173 A_24_P937405 PRSS23 protease, serine, 23 ‐1,76082169 1,96E‐05 ‐1,03313193 2,87E‐03 ‐1,17759475 5,71E‐03
NM_007350 A_23_P76450 PHLDA1 pleckstrin homology-like domain, family A, member 1 ‐1,69903751 3,40E‐05 ‐1,4769497 3,89E‐04 ‐1,4811118 2,35E‐03
NM_014331 A_32_P165477 SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 ‐2,08047468 6,45E‐06 ‐2,14489415 3,86E‐05 ‐1,23562508 4,67E‐03
NM_014417 A_23_P382775 BBC3 BCL2 binding component 3 ‐1,00732159 4,17E‐04 ‐1,33654378 6,77E‐04 ‐1,23073552 4,85E‐03
NM_015515 A_23_P78248 KRT23 keratin 23 (histone deacetylase inducible) ‐1,83350968 1,85E‐05 ‐1,32441993 6,83E‐04 ‐1,26026537 4,35E‐03
NM_019050 A_24_P137522 USP53 ubiquitin specific peptidase 53 ‐1,35699793 1,87E‐04 ‐1,29991961 8,52E‐04 ‐1,09717863 9,11E‐03
NM_019058 A_23_P104318 DDIT4 DNA-damage-inducible transcript 4 ‐0,92606048 3,03E‐04 ‐1,3922176 5,19E‐04 ‐1,19533261 5,31E‐03
NM_021158 A_24_P305541 TRIB3 tribbles homolog 3 (Drosophila) ‐1,26830874 3,14E‐03 ‐2,22619136 1,48E‐04 ‐1,99878018 1,79E‐03
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NM_023037 A_23_P105862 FRY furry homolog (Drosophila) ‐1,58604354 1,74E‐04 ‐1,15620552 1,97E‐03 ‐1,14045508 7,02E‐03
NM_024111 A_23_P14863 CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) ‐1,23800755 9,10E‐05 ‐1,14978915 1,88E‐03 ‐1,14312725 6,96E‐03
NM_032621 A_23_P22735 BEX2 brain expressed X-linked 2 ‐1,43746385 1,97E‐05 ‐1,33027821 6,84E‐04 ‐1,46674838 2,53E‐03
NM_032772 A_23_P202484 ZNF503 zinc finger protein 503 ‐1,46634134 3,01E‐04 ‐1,2218935 1,21E‐03 ‐1,14919162 6,32E‐03
NM_058179 A_23_P259692 PSAT1 chromosome 8 open reading frame 62; phosphoserine aminotransferase 1 ‐1,09216315 3,70E‐04 ‐1,2851445 1,33E‐03 ‐1,06783684 9,49E‐03
NM_144505 A_23_P369343 KLK8 kallikrein-related peptidase 8 ‐2,3099324 7,71E‐04 ‐1,23426937 1,08E‐03 ‐1,54530491 2,88E‐03
NM_148898 A_24_P38316 FOXP2 forkhead box P2 ‐1,16257205 3,45E‐04 ‐1,46460559 4,79E‐04 ‐1,27051843 5,70E‐03
NM_153478 A_24_P11061 CSAG1 chondrosarcoma associated gene 1 ‐2,00142153 1,89E‐04 ‐2,09838797 3,03E‐04 ‐2,23168982 2,25E‐04
NM_171998 A_24_P408603 RAB39B RAB39B, member RAS oncogene family ‐1,52450725 2,86E‐04 ‐1,09278857 2,07E‐03 ‐1,45376668 2,98E‐03
NM_173698 A_23_P345808 FAM133A family with sequence similarity 133, member A ‐4,08705351 1,87E‐06 ‐5,63321118 8,88E‐06 ‐1,64580833 1,77E‐03
NM_182707 A_24_P392110 PSG8 pregnancy specific beta-1-glycoprotein 7; pregnancy specific beta-1-glycoprotein 8; pregnancy specific be ‐2,52811923 4,24E‐06 ‐1,47525321 4,15E‐04 ‐1,2884775 3,96E‐03
NM_182757 A_24_P406060 RNF144B ring finger protein 144B ‐3,98861218 1,23E‐06 ‐1,88007321 1,21E‐04 ‐1,25415931 7,31E‐03
NM_183376 A_23_P339818 ARRDC4 arrestin domain containing 4 ‐1,6682404 1,67E‐03 ‐1,93675889 7,42E‐05 ‐1,68108966 2,36E‐03
NM_198461 A_32_P190303 LONRF2 LON peptidase N-terminal domain and ring finger 2 ‐1,16022619 1,47E‐03 ‐1,86532483 1,88E‐04 ‐1,77632568 1,17E‐03
NM_203403 A_23_P83007 C9orf150 chromosome 9 open reading frame 150 ‐2,51188422 3,88E‐04 ‐2,60612569 9,67E‐06 ‐1,9019306 1,29E‐03
NM_207446 A_23_P100001 LOC400451 family with sequence similarity 174, member B ‐4,1202078 7,05E‐06 ‐3,04001545 5,89E‐06 ‐3,07287002 5,25E‐05
NR_015370 A_23_P58538 chromosome 5chromosome 5 open reading frame 26 ‐1,05905921 1,95E‐04 ‐1,17500604 1,40E‐03 ‐1,24873723 4,90E‐03
NR_033888 A_24_P882959 LOC284344 Homo sapiens uncharacterized LOC284344 (LOC284344), non-coding RNA ‐1,81421343 7,95E‐05 ‐1,26512158 1,25E‐03 ‐1,18898504 9,21E‐03
Log 2 FC P value Log 2 FC P value Log 2 FC P value
ENST0000024 A_24_P535256 ENST0000024 ENST00000242208 3,4495517 9,72E‐06 2,75864448 1,05E‐05 1,82524492 0,00217015
NM_005012 A_32_P4018 ROR1 receptor tyrosine kinase-like orphan receptor 1 1,30283884 0,0010761 1,4226011 0,00084521 1,32838946 0,0034485
NM_032554 A_23_P394246 HCAR1 hydroxycarboxylic acid receptor 1 3,13840381 1,40E‐05 2,27924136 7,35E‐05 1,74639699 0,00119794
NM_032888 A_23_P158096 COL27A1 collagen, type XXVII, alpha 1 2,81024944 3,29E‐06 2,12891847 5,87E‐05 1,63171763 0,00252617
NM_000093 A_23_P158593 COL5A1 collagen, type V, alpha 1 1,64029408 0,00014023 2,26156607 2,37E‐05 1,44663007 0,00334751
NM_000358 A_23_P156327 TGFBI transforming growth factor, beta-induced, 68kDa 2,80880325 3,68E‐05 3,81845776 3,82E‐06 2,3140582 0,00021414
NM_000428 A_23_P218144 LTBP2 latent transforming growth factor beta binding protein 2 2,193703 0,00032987 1,36893566 0,0006058 1,50946873 0,00447424
NM_000575 A_23_P72096 IL1A interleukin 1, alpha 4,86449141 1,87E‐06 2,52702853 1,05E‐05 0,49369335 0,2022043
NM_000610 A_23_P24870 CD44 CD44 molecule (Indian blood group) 1,82579518 4,54E‐05 1,29534947 0,00079437 1,06257404 0,00973226
NM_000676 A_23_P55477 ADORA2B hypothetical LOC100131909; adenosine A2b receptor 2,15785283 7,05E‐06 1,27540873 0,00117234 1,21517596 0,00497849
NM_000852 A_23_P202658 GSTP1 glutathione S-transferase pi 1 3,20785566 3,34E‐05 2,89560413 1,15E‐05 5,56786645 6,37E‐06
NM_000930 A_23_P82868 PLAT plasminogen activator, tissue 2,92014795 2,23E‐06 2,86176488 5,44E‐06 1,26695125 0,00445263
NM_0010401 A_23_P8452 LFNG LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 2,14012398 1,47E‐05 2,36719695 1,70E‐05 1,70620911 0,00132041
NM_0010805 A_32_P52414 LOC644943 Ras association (RalGDS/AF-6) domain family (N-terminal) member 10 2,01940409 0,00123561 2,90719901 1,06E‐05 3,4273124 5,12E‐05
NM_001409 A_24_P926960 MEGF6 multiple EGF-like-domains 6 1,1308263 0,00118809 1,38102082 0,00074941 0,74476166 0,04080211
NM_002165 A_23_P252306 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 1,85010354 1,62E‐05 1,4674131 0,00047408 1,40446158 0,00295129
NM_002167 A_23_P137381 ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1,13698227 0,00014229 1,17194042 0,00168606 1,13781983 0,00659747
NM_002178 A_23_P139912 IGFBP6 insulin-like growth factor binding protein 6 2,17737016 4,40E‐06 2,08349049 5,67E‐05 1,42906818 0,00312489
NM_002192 A_23_P122924 INHBA inhibin, beta A 3,34695573 4,45E‐06 2,91142459 5,44E‐06 1,55485994 0,0020654
NM_002318 A_23_P111995 LOXL2 lysyl oxidase-like 2 1,57115991 3,56E‐05 1,48596967 0,00039221 1,16303028 0,00597385
NM_002341 A_23_P93348 LTB lymphotoxin beta (TNF superfamily, member 3) 4,38910213 2,83E‐06 3,43222314 5,44E‐06 1,50379139 0,00306967
NM_002751 A_23_P502274 MAPK11 mitogen-activated protein kinase 11 2,06921509 1,64E‐05 1,46188256 0,00041398 1,26296329 0,00593456
NM_003012 A_23_P10127 SFRP1 secreted frizzled-related protein 1 3,38233813 7,65E‐06 3,29062341 5,44E‐06 5,14603198 6,37E‐06
NM_003088 A_23_P168531 FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) 2,50677701 3,46E‐05 1,62291075 0,00035597 1,09130434 0,00876387
NM_003246 A_23_P206212 THBS1 thrombospondin 1 3,37607996 1,95E‐05 2,91622092 5,44E‐06 1,22455685 0,0063206
NM_003264 A_23_P92499 TLR2 toll-like receptor 2 2,904175 3,24E‐05 2,08635311 0,00013044 1,21870916 0,00489826
NM_003494 A_23_P39925 DYSF dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) 2,1937892 1,40E‐05 1,63096776 0,00025711 1,49991476 0,00236278
NM_003588 A_23_P422178 CUL4B cullin 4B 0,64342805 0,00745917 1,62356929 0,00028589 1,3598221 0,00312222
NM_003733 A_23_P139786 OASL 2'-5'-oligoadenylate synthetase-like 2,57422695 8,44E‐05 2,54860934 9,02E‐06 1,91915364 0,00095544
NM_004460 A_23_P56746 FAP fibroblast activation protein, alpha 5,39496843 9,05E‐07 4,77699852 2,16E‐06 4,02339409 1,85E‐05
NM_004753 A_23_P33759 DHRS3 dehydrogenase/reductase (SDR family) member 3 2,20445645 3,34E‐05 1,60821553 0,00027451 1,27020485 0,00428201
NM_004994 A_23_P40174 MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 2,24730803 2,83E‐06 1,77389168 0,00015004 1,04873192 0,00940379
NM_005429 A_23_P167096 VEGFC vascular endothelial growth factor C 3,1671143 2,71E‐06 2,00963852 0,00024478 1,52382508 0,00285125
NM_005725 A_23_P201193 TSPAN2 tetraspanin 2 1,90595797 5,32E‐05 2,10056978 5,06E‐05 1,31110511 0,00370411
NM_005823 A_23_P77529 MSLN mesothelin 0,80726104 0,00547454 1,8557777 0,00013593 1,48933316 0,00283113
NM_006417 A_23_P23074 IFI44 interferon-induced protein 44 2,87859612 1,06E‐05 2,79779509 5,89E‐06 2,03208076 0,00044277
NM_006897 A_23_P25150 HOXC9 homeobox C9 1,94806845 0,00023853 1,80660472 0,0002962 1,63448271 0,0036561
NM_006936 A_23_P102937 SUMO3 SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae) pseudogene; SMT3 suppressor of mif two 3 0,8361159 0,00410646 1,01719451 0,00367611 1,117685 0,00712696
NM_007289 A_24_P260101 MME membrane metallo-endopeptidase 0,8168381 0,00693129 1,24306003 0,00105343 0,7019343 0,05419134
NM_014256 A_23_P78980 B3GNT3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 2,39803785 7,14E‐06 1,21272689 0,00125079 1,77586456 0,00121201
NM_014350 A_32_P219520 TNFAIP8 tumor necrosis factor, alpha-induced protein 8 1,06953295 0,00114313 1,09599389 0,00331229 1,05042516 0,00941858
NM_016235 A_23_P324327 GPRC5B G protein-coupled receptor, family C, group 5, member B 2,32040176 3,83E‐05 1,92159657 7,94E‐05 1,6169327 0,00543052
NM_017654 A_23_P355244 SAMD9 sterile alpha motif domain containing 9 1,15433736 0,00031326 1,27265962 0,00087128 1,2459451 0,00629024
NM_018602 A_23_P206140 DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 1,90273976 0,00250654 4,03422988 3,13E‐06 2,96510379 0,00015874
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NM_020134 A_23_P210224 DPYSL5 dihydropyrimidinase-like 5 1,84146402 1,64E‐05 1,22727201 0,00111669 1,47884867 0,00234838
NM_021071 A_23_P116902 ART4 ADP-ribosyltransferase 4 (Dombrock blood group) 1,849363 0,00787111 1,77604652 0,00031777 1,53876511 0,00306597
NM_021629 A_32_P171313 GNB4 guanine nucleotide binding protein (G protein), beta polypeptide 4 2,18971734 1,85E‐05 1,87336873 0,00010921 1,2461904 0,00447424
NM_022370 A_23_P356581 ROBO3 roundabout, axon guidance receptor, homolog 3 (Drosophila) 2,4008704 4,54E‐05 1,64022292 0,00047275 1,33342014 0,00343007
NM_025135 A_32_P34444 FHOD3 formin homology 2 domain containing 3 4,10351737 1,07E‐05 3,86856762 5,44E‐06 2,15478103 0,00166461
NM_025179 A_23_P46618 PLXNA2 plexin A2 3,19528483 5,96E‐06 1,96905162 6,77E‐05 1,61377018 0,00287726
NM_030775 A_23_P53588 WNT5B wingless-type MMTV integration site family, member 5B 2,03949498 0,00055932 1,74557366 0,00038816 1,61532611 0,0016596
NM_030955 A_32_P103220 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 2,44605665 2,05E‐05 2,74427443 5,93E‐06 2,21406233 0,00022686
NM_032413 A_23_P26024 C15orf48 chromosome 15 open reading frame 48 5,8889039 9,05E‐07 4,59532803 2,16E‐06 2,95210513 5,25E‐05
NM_032587 A_23_P41854 CARD6 caspase recruitment domain family, member 6 1,63727421 7,72E‐05 1,59568454 0,00038816 1,26003906 0,0063206
NM_138711 A_23_P252062 PPARG peroxisome proliferator-activated receptor gamma 2,178288 1,14E‐05 1,60375259 0,00038238 1,32264733 0,00376812
NM_138768 A_23_P360240 MYEOV myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas) 1,6338799 0,00027 1,78456231 0,00013592 1,5658368 0,00267157
NM_152703 A_23_P145874 SAMD9L sterile alpha motif domain containing 9-like 2,40778834 8,87E‐06 1,5074545 0,00037234 1,34942225 0,00699606
NM_172229 A_23_P77612 KREMEN2 kringle containing transmembrane protein 2 1,68625263 1,81E‐05 1,21097049 0,00114599 1,27440774 0,00543052
NM_176072 A_23_P24903 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 1,47009792 4,60E‐05 1,1897628 0,00125637 1,06418491 0,00917063
NM_182755 A_23_P161156 ZNF438 zinc finger protein 438 2,47978681 5,85E‐05 2,72025567 0,00013848 2,83450713 6,26E‐05
NM_198129 A_24_P687302 LAMA3 laminin, alpha 3 2,51712884 2,07E‐05 1,58203896 0,00099137 1,22698646 0,01184986
NM_206967 A_24_P289178 C16orf74 chromosome 16 open reading frame 74 2,50235533 2,32E‐06 1,51491943 0,000344 1,27585318 0,00478496
NR_015379 A_32_P200238 UCA1 urothelial cancer associated 1 1,2258268 8,12E‐05 1,45323115 0,00041949 1,28564612 0,00412749
XR_110477 A_32_P158019 LOC10050594PREDICTED: Homo sapiens uncharacterized LOC100505940 1,3192231 0,00046213 1,83220714 0,0002962 1,29626969 0,00643079
Supplementary Table S1: Oligonucleotide Primers 
 
Primer Direction Sequence Reference 
TMPRSS2 :ERG 
(Cloning) 
Forward 5’- CGCGAGCTAAGCAGGAGGC -3’ 
This study 
Reverse 5’- CCTCCGCCAGGTCTTTAGTA -3’ 
TMPRSS2:ERG 
(Classical PCR) 
Forward 5’- CGCGAGCTAAGCAGGAGGC -3’ 
(1) 
Reverse 5’- GTAGGCACACTCAAACAACGACTGG- 3’ 
ERG (qPCR) 
Forward 5’- AACGAGCGCAGAGTTATCGT -3’ This study 
(Effeciency: 99.8%) Reverse 5’- GTGAGCCTCTGGAAGTCGTC -3’ 
MMP9 (qPCR) 
Forward 5’- AAGTGGCACCACCACAACATC -3’ (2)  
(Effeciency: 98.3%) Reverse 5’- CAAAGGCGTCGTCAATCACC -3’ 
PLXNA2 (qPCR) 
Forward 5’-GGAGCCACTCTTCATGCTATACTGT-3’ (3)  
(Effeciency: 99.1%) Reverse 5’- GTTGACGCAGTTCAGGATCA-3’ 
18s (qPCR) 
Forward 5’- CAGCTTCCGGGAAACCAAAGTC-3’ 
(4) 
Reverse 5’- AATTAAGCCGCAGGCTCCACTC-3’ 
pMMP9 (ChIP) 
Forward 5’- TGCGGACTTACAACCTACAGTG-3’ 
(5) 
Reverse 5’- TCTTTGACTCAGCTTCCTCTCC-3’ 
pPLXNA2 (ChIP) 
Forward 5’- CCGCTTCCGGAAAGCCGTGT-3’ 
This study 
Reverse 5’- GTCCCGACTTGCATGGGGGC-3’ 
pGAPDH (ChIP) 
Forward 5’- GCGTGCCCAGTTGAACCA-3’ 
(6) 
Reverse 5’- CGCCCGTAAAACCGCTAGT-3’ 
CHD1 (qPCR) 
Forward 5’- CCCACCACGTACAAGGGTC-3’ 
* (Effeciency: 99.3%) 
Reverse 5’- CTGGGGTATTGGGGGCAT-3’ 
VIM (qPCR) 
Forward 5’- GAGAACTTTGCCGTTGAAGC-3’ 
* (Effeciency: 97.6%) 
Reverse 5’- GCTTCCTGTAGGTGGCAATC-3’ 
TWIST1 (qPCR) 
Forward 5’-GCAGGACGTGTCCAGCTC-3’ 
* (Effeciency: 99.1%) 
Reverse 5’- CTGGCTCTTCCTCGCTGTT-3’ 
Primer Direction Sequence Reference 
SNAI1/SNAIL 
(qPCR) 
Forward 5’- AATCGGAAGCCTAACTACAGCG-3’ 
* (Effeciency: 96.3%) 
Reverse 5’- GTCCCAGATGAGCATTGGCAA-3’ 
SNAI2/SLUG 
(qPCR) 
Forward 5’- ATACCACAACCAGAGATCCTCA-3’ 
* (Effeciency: 99.8%) 
Reverse 5’- GACTCACTCGCCCCAAAGATG-3’ 
 
* These primers have been cited by multiple publications. 
1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of 
TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005 Oct 28;310(5748):644-8. 
2. Kato T, Fujita Y, Nakane K, Kojima T, Nozawa Y, Deguchi T, et al. ETS1 promotes chemoresistance 
and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and 
MMP9 expression. Biochem Biophys Res Commun. 2012 Jan 20;417(3):966-71. 
3. Gabrovska PN, Smith RA, Tiang T, Weinstein SR, Haupt LM, Griffiths LR. Semaphorin-plexin 
signalling genes associated with human breast tumourigenesis. Gene. 2011 Dec 10;489(2):63-9. 
4. Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, et al. Role of cationic 
channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res. 
2009 Feb 1;70(3):1225-35. 
5. Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for optimal epidermal growth factor 
receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res. 
2007 May;5(5):413-21. 
6. Boulay G, Dubuissez M, Van Rechem C, Forget A, Helin K, Ayrault O, et al. Hypermethylated in 
cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through 
interaction with human polycomb-like (hPCL) proteins. J Biol Chem. 2011 Mar 23;287(13):10509-24. 
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